United Therapeutics Corp

UTHR remains in a Stage 4 decline with a bearish medium-term bias reinforced by lower highs & lower lows and a decisive support failure. Price has rallied into declining 9/20 EMAs and faced rejection, offering a favorable sell entry at the EMA cluster. Although oversold, the rejection at moving averages aligns with continued downtrend, supporting immediate sell execution.

• ↑Q1 revenue $782M (+11% YoY) driven by Tyveso $458M (+9% YoY)
• ↑Forecasting $4B revenue run rate by end-2027 with pipeline launches
• ↓Rising PAH entrants like Eutrepia and generics pressuring market share